Keen Therapeutics

Since its establishment, Keen Therapeutics has rapidly built a de novo drug design platform based on first principles, enabling systematic exploration of the entire chemical space and enhancing the virtual discovery capabilities for novel targets. By efficiently integrating upstream and downstream partners, the team maximizes internal and external R&D synergies, significantly improving the efficiency of the DMTA cycle while reducing trial-and-error costs and timelines. Leveraging the iterative optimization capability of this discovery platform, the company has made significant progress in multiple early-stage targets within the field of cancer metabolism in less than a year. The team focuses on unmet clinical needs in oncology and immunology, targeting early-stage candidates with translational advantages to deliver first-in-class small molecule drugs to patients in the shortest possible time. Shortly after its founding, the company garnered attention from global pharmaceutical giants and became one of the first companies to join the Roche China Accelerator.